Research Signal – Source date 2025-07-01
A fall can change an older person’s life in an instant. Age-related conditions such as osteoporosis, muscle loss and impaired balance can make falls and traumatic injury more likely. After spinal cord injury, older people also tend to have poorer neurological recovery than younger patients. A review published July 1, 2025, examines one possible contributor: inflammation in the injured spinal cord that may remain active long after the initial damage.
The review brings together proposed mechanisms, findings from animal studies and possible treatment directions. It is not a new trial in patients. Its central question is how ageing may change the body’s response to injury, and whether that difference could eventually guide care.
The response continues after the initial impact
Spinal cord injury begins with a mechanical insult. The tissue damage can then set off secondary processes, including reduced blood flow, cell death and inflammation. This response is part of the injury’s changing course: immune cells arrive, inflammatory signals rise, and in a more successful recovery the response eases as repair begins.
The review describes three broad periods. In the first 24 hours, the response is initiated. During the following days, immune activity intensifies; different inflammatory signals rise on different schedules. Neutrophils appear early, while monocytes and macrophages become prominent later in the peak period. Astrocytes also multiply and gather around the lesion.
Over the following weeks, inflammation should subside. But the review describes animal studies in which immune activity persists well beyond the acute period. In one contusion model, activated microglia and macrophages were found from one to 12 weeks after injury, including in white matter some distance from the lesion. In a compression model, levels of the inflammatory cytokines IL-1β and IL-6 remained elevated at 28 days.
These observations show that inflammation can outlast the initial injury in experimental models. They do not establish how long it persists in any individual patient. The concern raised by the review is that ageing may make the transition toward resolution more difficult.
An older spinal cord may start closer to an inflammatory threshold
The review describes an aged spinal cord as a changed immune environment even before injury. In experimental work, microglia—the resident immune cells of the central nervous system—can appear “primed,” with altered shapes and elevated inflammatory signals. Some studies also report more T cells and monocytes around blood vessels and within spinal tissue.
This low-grade state, often called inflammaging, may leave less room for a measured response when injury occurs. The review cites experiments in which comparable injury stimuli prompted roughly twice the release of pro-inflammatory cytokines in aged spinal cords than in young controls. That is an animal-model observation, not a prediction that an older person will have a particular response or outcome.
Ageing may also affect how inflammation switches off. The review describes immunosenescence, or age-related changes in immune function, as a shift that can favor inflammatory activity while reducing anti-inflammatory signals such as IL-10. At the same time, senescent cells can release signals that attract and activate nearby immune cells. The result may be a local environment that sustains inflammatory activity rather than clearing it efficiently.
Cellular cleanup matters too. Autophagy helps remove damaged cell parts, including dysfunctional mitochondria. The review connects impaired autophagy and mitochondrial damage with increased oxidative stress and inflammatory signaling in aged injury models. In that proposed cycle, damaged mitochondria add inflammatory signals, while inflammation and oxidative stress make cellular damage harder to contain.
Together, these mechanisms offer a possible explanation for why the same injury could prompt a more intense or prolonged response in an older organism. The review draws substantially on preclinical evidence, so the mechanisms are a basis for investigation rather than a settled account of recovery in older patients.
The glial scar protects and restricts
Astrocytes help form a boundary around spinal cord damage. Along with other cells, they contribute to the glial and fibrotic scar that can limit the spread of injury and inflammation. This containment role matters: a scar is not simply a harmful obstruction.
The boundary can also make regrowth harder. Around the lesion, astrocytes can add extracellular material, including chondroitin sulfate proteoglycans, collagen and fibronectin. These materials form physical and chemical barriers that impede axon growth. The scar’s two roles make broad suppression of the response a difficult proposition: reducing inflammation or scar formation could interfere with containment as well as with processes that constrain regeneration.
The therapeutic challenge is therefore not just to turn inflammation down. It is to understand which signals and cells should be changed, when, and in which patients, while preserving useful parts of the tissue response.
Candidate treatments target different parts of the cycle
The review discusses several possible approaches, but it does not establish that any improves recovery in older people with spinal cord injury.
One approach is to suppress inflammatory signaling. In young animal models, IL-1 receptor antagonist (IL-1RA) has reduced acute inflammation and the entry of inflammatory cells into the lesion. NLRP3 inflammasome inhibitors, including MCC950, have also reduced inflammatory cytokine levels and improved functional recovery in young mice. The age gap matters: the review flags possible infection and wound-healing concerns with systemic immune suppression in older people, as well as limited understanding of how ageing changes drug handling and immune responses. Effects seen in young animals cannot by themselves tell clinicians whether these treatments would be safe or helpful in older patients.
A second strategy aims to clear senescent cells. The review describes mouse-model findings in which senescent-cell removal was associated with improved motor and sensory function, more preserved myelin and reduced scar formation and inflammatory cytokine release. These are promising experimental results, but they do not answer how such treatment would perform in older people or establish a safe clinical approach.
A third line of research uses exosomes, small cell-derived packages that can carry regulatory signals such as microRNAs. The review discusses candidates intended to reduce inflammatory activity in glial cells. It also identifies basic translational questions, including how to prepare and deliver these packages and whether they remain safe and effective over time in aged models. A proposed signal is not yet a demonstrated treatment benefit.
Each strategy addresses a different point in the inflammatory cycle. The open question is whether a targeted intervention can help an older injured spinal cord without disrupting functions needed for protection and repair.
Young models and varied patients complicate the comparison
Much of the treatment evidence discussed in the review comes from young animals. Those models can help identify mechanisms, but they may miss the baseline inflammation, tissue ageing and other changes that shape response in older organisms. The review calls for more consistent aged-injury models and broader functional assessments, rather than relying on a single measure of movement.
Older patients also differ from one another. Age alone does not describe injury severity, frailty or other illnesses. The review proposes that future research consider these features alongside biological markers, but the biomarkers and stratification approaches it discusses are not established clinical decision tools.
That variation affects what a trial can show. Results may depend on who was enrolled, the severity of injury and the health conditions participants bring with them. More representative studies in older people, supported by better age-relevant preclinical work, are needed to judge both benefit and safety.
How age-tailored care could change recovery
For an older person with spinal cord injury, care that accounts for inflammatory state alongside injury severity and other health conditions could eventually make treatment and rehabilitation more responsive to individual needs. If research can identify reliable markers and confirm safe, useful approaches in representative aged models and clinical studies, that tailoring could support better functional recovery and daily life. The review describes a direction for research; that benefit remains a possibility to test.
Key Sources
- Primary source: Spinal Cord Injury and Ageing: The Role of Chronic Neuroinflammation.
DOI or Journal Page · Review or Meta-Analysis · 2025-07-01
Keep exploring